Recrutamento encerrado
FASE
Número Europeu 2014-002048-42
PEREX
A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
Detalhes
Destaques